Tech Company Financing Transactions
Therabron Therapeutics Funding Round
Therabron Therapeutics, based in Rockville, received $6.8 million in investment from Brace Pharma and private investors.
Transaction Overview
Company Name
Announced On
11/10/2015
Transaction Type
Venture Equity
Amount
$6,750,000
Round
Series B
Investors
Brace Pharma (Lead Investor)
Proceeds Purpose
The Company's lead product candidate, CG100, is currently being investigated in a phase 2 clinical trial for the prevention of chronic respiratory morbidities (CRM) in preterm infants. Therabron anticipates enrollment for this study to be completed by the end of 2015.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9430 Key W Ave. 150
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Not Recorded
Overview
At Therabron Therapeutics, we are working to change how respiratory diseases are managed. We are aiming to not only provide symptomatic relief, but also to improve long-term health outcomes and reduce healthcare costs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Miller
Chief Financial Officer
Linda Chang
Chief Scientific Officer
Aprile Pilon
Browse more venture capital transactions:
Prev: 11/10/2015: Qvivr venture capital transaction
Next: 11/10/2015: MiRagen Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document tech company VC transactions. VC transactions on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs